Lifecare ASA — Capital/Financing Update 2026

May 29, 2026

Lifecare ASA: Exercise price for Warrants Series 2 issued in connection with the Rights Issue

Lifecare ASA: Exercise price for Warrants Series 2 issued in connection with the Rights Issue

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED

STATES, CANADA, AUSTRALIA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE

PEOPLE'S REPUBLIC OF CHINA, JAPAN OR ANY OTHER JURISDICTION IN WHICH THE

DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE.

Reference is made to the stock exchange announcement by Lifecare ASA (the

"Company") on 22 January 2026 regarding the final results of the partially

underwritten rights issue of new shares in the Company (the "Rights Issue").

Reference is also made to the announcement made by the Company on 30 January

2026 with information regarding the warrants issued in connection with the

Rights Issue.

A total of 129,000,033 warrants series 2 with ISIN NO0013709204 ("Warrants

Series 2") were allocated and delivered to the subscribers in and the

underwriters of the Rights Issue, pursuant to resolutions by the Company's

extraordinary general meeting held on 2 January 2026.

Each Warrant Series 2 gives the holder a right to subscribe for one new share

in the Company, each with a nominal value of NOK 0.10.

Warrants Series 2 may be exercised during the exercise period from 09:00 hours

(CEST) on 1 June 2026 to 16:30 hours (CEST) on 12 June 2026 (the "Exercise

Period"), at a subscription price per new share equal to 70% of the

volume-weighted average price (VWAP) of the Company's shares on Euronext Oslo

Børs on the last ten (10) trading days prior to the first date of the Exercise

Period, but in any event not exceeding NOK 0.625 (the subscription price in

the Rights Issue plus 25%). The subscription price may not be lower than the

par value of the Company's shares.

Based on the criteria above, the exercise price for Warrants Series 2 is NOK

0.24899 per new share.

Warrant Series 2 are listed and tradable on Euronext Oslo Børs under the

ticker code "LIFES". The trading in Warrants Series 2 will be halted five

trading days before the end of the Exercise Period to facilitate settlement of

exercised Warrants Series 2. Warrants Series 2 will thus be tradable until

16:30 hours (CEST) on 5 June 2026.

Warrants Series 2 not sold within 5 June 2026 at 16:30 (CEST) or exercised

within 12 June 2026 at 16:30 (CEST) will lapse with no compensation to the

holders. Holders of Warrants Series 2 who do not exercise their Warrants

Series 2 within the Exercise Period may experience a dilution of their

shareholding in the Company.

The exercise of Warrants Series 2 must be done through the submission of an

exercise form to the Managers (as defined below) or through the VPS online

subscription system, within the Exercise Period. Further information regarding

the exercise procedure, including weblinks to the exercise form, will be

provided in a separate stock exchange announcement to be published by the

Company before commencement of the Exercise Period.

DNB Carnegie, a part of DNB Bank ASA, and SB1 Markets AS act as managers in

the Rights Issue and the warrants exercise (the "Managers").

Important information

This announcement does not constitute an offer of securities for sale or a

solicitation of an offer to purchase securities of the Company in the United

States or any other jurisdiction. Copies of this announcement may not be sent

to jurisdictions, or distributed in or sent from jurisdictions, in which this

is barred or prohibited by law. The securities of the Company may not be

offered or sold in the United States absent registration or an exemption from

registration under the U.S. Securities Act of 1933, as amended (the "U.S.

Securities Act"). The securities of the Company have not been, and will not

be, registered under the U.S. Securities Act. Any sale in the United States of

the securities mentioned in this communication will be made solely to

"qualified institutional buyers" as defined in Rule 144A under the U.S.

Securities Act. No public offering of the securities will be made in the

United States.

This announcement is an advertisement and is not a prospectus for the purposes

of Regulation (EU) 2017/1129 of the European Parliament and of the Council of

14 June 2017 on prospectuses to be published when securities are offered to

the public or admitted to trading on a regulated market, and repealing

Directive 2003/71/EC (as amended) as implemented in any EEA Member State (the

"Prospectus Regulation").

This announcement is not for publication or distribution in, directly or

indirectly, Australia, Canada, Japan, the United States, or any other

jurisdiction in which such release, publication or distribution would be

unlawful, and it does not constitute an offer or invitation to subscribe for

or purchase any securities in such countries or in any other jurisdiction. In

particular, the document and the information contained herein should not be

distributed or otherwise transmitted into the United States or to publications

with a general circulation in the United States of America.

The Managers are acting for the Company in connection with the Rights Issue

and no one else and will not be responsible to anyone other than the Company

for providing the protections afforded to their respective clients or for

providing advice in relation to the Rights Issue or any transaction or

arrangement referred to in this announcement.

Matters discussed in this announcement may constitute forward-looking

statements. Forward-looking statements are statements that are not historical

facts and may be identified by words such as "anticipate", "believe",

"continue", "estimate", "expect", "intends", "may", "should", "will" and

similar expressions. The forward-looking statements in this release are based

upon various assumptions, many of which are based, in turn, upon further

assumptions. Although the Company believes that these assumptions were

reasonable when made, these assumptions are inherently subject to significant

known and unknown risks, uncertainties, contingencies, and other important

factors which are difficult or impossible to predict and are beyond its

control. Such risks, uncertainties, contingencies, and other important factors

could cause actual events to differ materially from the expectations expressed

or implied in this release by such forward-looking statements. The

information, opinions and forward-looking statements contained in this

announcement speak only as at its date and are subject to change without

notice. This announcement is made by and is the responsibility of the Company.

Neither the Managers nor any of their respective affiliates make any

representation as to the accuracy or completeness of this announcement and

none of them accepts any responsibility for the contents of this announcement

or any matters referred to herein.

This announcement is for information purposes only and is not to be relied

upon in substitution for the exercise of independent judgment. It is not

intended as investment advice and under no circumstances is it to be used or

considered as an offer to sell, or a solicitation of an offer to buy any

securities or a recommendation to buy or sell any securities of the Company.

No reliance may be placed for any purpose on the information contained in this

announcement or its accuracy, fairness, or completeness. Neither the Managers

nor any of their respective affiliates accept any liability arising from the

use of this announcement.

About us

Lifecare ASA is a medical sensor company developing technology for sensing and

monitoring of various body analytes. Lifecare's focus is to bring the next

generation of Continuous Glucose Monitoring systems to market. Lifecare

enables osmotic pressure as sensing principle. Lifecare's sensor technology is

suitable for identifying and monitoring the occurrence of a wide range of

analytes and molecules in the human body and in pets.

Contacts

For further information, please contact:

Joacim Holter, CEO, joacim.holter@lifecare.no, +47 40 05 90 40

Petter Nielsen, CFO, petter.nielsen@lifecare.no, +47 92 24 74 64

This information is subject to disclosure under the Norwegian Securities

Trading Act, §5-12. The information was submitted for publication, through the

agency of the contact persons set out above, at 2026-05-29 18:55 CEST.